## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($87.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Texas Permanent School Fund Corp Reduces Stock Holdings in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251215T130746 | Neutral | Relevance: 100%
- Texas Permanent School Fund Corp decreased its stake in Boston Scientific Corporation by 24.1% during the second quarter, selling 51,169 shares. Despite this reduction, other institutional investors like Vanguard Group Inc., State Street Corp, and Geode Capital Management LLC increased their holdings in the medical equipment provider. Several analysts have maintained "outperform" or "overweight" ratings on Boston Scientific, with a consensus "Buy" rating and an average price target of $124.43.

**2. MASTERINVEST Kapitalanlage GmbH Invests $5.23 Million in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251215T050736 | Bullish | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH recently acquired a new stake of 48,728 shares in Boston Scientific (NYSE:BSX), valued at approximately $5.23 million. This investment comes as Boston Scientific reported strong quarterly earnings, beating expectations with $0.75 EPS and $5.07 billion revenue. Analyst sentiment remains positive, with a consensus "Buy" rating and an average price target of $124.43.

**3. Boston Scientific Corporation $BSX Stock Position Boosted by Fullerton Fund Management Co Ltd.**
- Source: MarketBeat | 20251214T115325 | Bullish | Relevance: 100%
- Fullerton Fund Management Co Ltd. significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 4.0% in the second quarter, making it their 10th-largest holding. This boost comes as institutional investors now own 89.07% of the stock, despite recent insider selling by executives. Boston Scientific exceeded Q3 earnings expectations and boasts a consensus "Buy" rating from analysts with an average target price of $124.43.

**4. National Bank of Canada FI Has $150.83 Million Holdings in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251214T110317 | Somewhat-Bullish | Relevance: 100%
- National Bank of Canada FI significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 61.3% in the second quarter, holding over 1.4 million shares valued at $150.83 million. Other institutional investors like Vanguard Group Inc., State Street Corp, Geode Capital Management LLC, Norges Bank, and Invesco Ltd. also modified their holdings of Boston Scientific stock. The article details Boston Scientific's financial performance, recent insider transactions, and analyst ratings, with the stock currently having an average rating of "Buy" and an average target price of $124.43.

**5. Pulling back 5.1% this week, Boston Scientific's NYSE:BSX) five-year decline in earnings may be coming into investors focus**
- Source: Yahoo Finance | 20251214T050736 | Neutral | Relevance: 100%
- Boston Scientific (NYSE:BSX) shareholders have seen impressive returns of 161% over the last five years, despite a recent 5.1% pullback and a 11% drop in the last month. However, the company's earnings per share have declined by 6.4% annually during this period. Revenue growth of 13% per year suggests management may be prioritizing top-line expansion over EPS.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Long-term trend broken: trading 8.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $136.7B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 26.6 |
| Current P/E | 30.4 |
| YoY Growth | 14.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -6.7% to -1.1% (+5.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (1.4%) - potential reversal signal. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram bearish (-0.76), momentum weakening. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.11% (CS: 18) | Neutral |
| RSI_14 | 32.5 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.949x | Below |
| vs SMA50 | 0.934x | Below |
| vs SMA200 | 0.912x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $92.19
- **Stop Loss:** $87.87 (4.7% risk)
- **Target:** $96.51 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 277
- **Position Value:** $25,536.63
- **Portfolio %:** 25.54%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*